The effect of bariatric surgery on health care utilization and costs among individuals with type 2 diabetes remains unclear.
O besity affects one third of the United States adults 1 and results in $147 billion of medical spending annually. 2 Excess body weight is the single greatest predictor of developing diabetes, 3 which is estimated to cost $153 billion in medical costs annually. 4 Bariatric surgery is an obesity intervention that produces sustained weight loss 5 and improvement in many obesity-related conditions, including diabetes. 6 Although there is a reduction in medical costs and prescription drug use after bariatric surgery, [7] [8] [9] [10] and sustained reductions in HbA1c, 11 there is little information about utilization and cost outcomes in patients with type 2 diabetes after bariatric surgery. Understanding costs and utilization in this population is important given that one third of all patients undergoing bariatric surgery have type 2 diabetes. 12 If bariatric surgery substantially reduces use of health care resources and overall medical costs in patients with type 2 diabetes, then bariatric surgery may prove to be cost saving.
The objective of this study was to examine the health care utilization and costs, in an insured cohort of individuals with type 2 diabetes after bariatric surgery, and compare this to utilization and costs before surgery. We hypothesized that total costs, pharmacy costs, hospitalizations and inpatient days, inpatient costs, specialist visits (eg, endocrinologists, cardiologists), and primary care visits would be persistently lower by the end of the first year after surgery and in subsequent years due to improvements in heath status. We also hypothesized that outpatient costs would be higher in the first year after surgery due to surgery-related follow-up visits and then lower by the end of the second and third postsurgical years due to improvements in heath status, and that hospital costs would be higher in the first year after surgery due to possible complications and then decline due to improvements in heath status. We tested these hypotheses using a large dataset of claims from beneficiaries insured by Blue Cross Blue Shield (BCBS).
METHODS

Design
This was a retrospective cohort study of individuals with type 2 diabetes who received bariatric surgery. In this study, we compared the postsurgical costs and utilization with the presurgical costs and utilization with the assumption that the presurgical measures reflect the experience of individuals with diabetes who do not undergo surgery.
Data
We obtained claims data from 2002 to 2008 from commercially insured individuals from 7 BCBS health plans providing coverage across the United States: BCBS of Tennessee, BCBS of Hawaii, BCBS of Michigan, BCBS of North Carolina, Highmark Inc. (of Pennsylvania), Independence Blue Cross (of Pennsylvania), Wellmark BCBS of Iowa, and Wellmark BCBS of South Dakota. Data from 2007 to 2008 were exclusively from Michigan and Highmark. The data included enrollment files, benefits information to determine medical and pharmacy coverage, and inpatient, outpatient, and pharmacy claims records containing International Classification of Disease-9 Clinical Modification (ICD-9) codes, Common Procedural Terminology codes, prescription National Drug Codes, and costs and charges (submitted, allowed, and paid).
The data were deidentified in accordance with the Health Insurance Portability and Accountability Act's definition of a limited dataset. The Johns Hopkins University Office of Research Subjects deemed the study to be exempt from federal regulations because the research activities were considered to be of minimal risk to patients.
Inclusion Criteria Analytic Cohort
BCBS beneficiaries were included in the analytic cohort if they had 6 months of continuous coverage in each of the 1-year intervals, including pharmacy coverage, before the date of bariatric surgery; were between 18 and 64 years of age, inclusive; did not have an ICD-9 code for cancer of the esophagus (ICD-9 150 to 150.9), stomach (ICD-9 151 to 151.9), small intestine (ICD-9 152 to 152.9) or pancreas (ICD-9 157 to 157.9), or malignant neoplasm without specification of site (ICD-9 199 to 199.2).
Individuals with Bariatric Surgery
BCBS beneficiaries were classified as having bariatric surgery if they had any of the ICD-9 procedure codes or Common Procedural Terminology codes for bariatric surgery as shown in Appendix A, Supplemental Digital Content 1, http://links.lww.com/MLR/A221. For 4 of the ICD-9 codes, we required that a code for morbid obesity (ICD-9 to 287.1) be present concurrent with the procedure code. If a relevant surgery was coded, but the primary diagnosis code indicated ulcer disease (Appendix A, Supplemental Digital Content 1, http://links.lww.com/MLR/A221), we excluded the individuals as the surgery was unlikely to have been primarily for treatment of obesity. We excluded individuals if they had a code indicating a revision procedure before the bariatric procedure of interest, suggesting that there had been an earlier bariatric surgery (Appendix A, Supplemental Digital Content 1, http://links.lww.com/MLR/A221).
Individuals With Type 2 Diabetes
BCBS beneficiaries were classified as having type 2 diabetes if they had 1 relevant inpatient code or 2 outpatient codes separated by at least 30 days (relevant codes: 250.xx, 648.0 diabetes mellitus with pregnancy; 362.0: diabetic retinopathy, or 266.41: diabetic cataract). Individuals were also classified as having diabetes if they filled a prescription for a medication for treatment of hyperglycemia anytime preceding surgery (Appendix B, Supplemental Digital Content 2, http://links.lww.com/MLR/A222). If the prescription was for metformin alone, the individual was also required to have an ICD-9 code for diabetes for inclusion in this group. Individuals who only had codes for type 1 diabetes (250.x3) or gestational diabetes (648.83) were excluded.
Outcomes
The utilization variables included the number of inpatient days, outpatient visits, and outpatient subspecialist visits; hereafter referred to as specialist visits (eg, endocrinologists, cardiologists). We also examined total annualized costs and several subcategories-inpatient costs, outpatient costs, pharmacy costs, and other costs (professional office and professional other)-which we standardized to adjust for differences in reimbursement between plans and for inflation over time. Professional office services refer to services rendered in an office and include things such as visit costs, laboratory costs, and diagnostic imaging. Professional other services refer to all other charges and include things such as diagnostic laboratory facilities, imaging facilities, home health care, or nursing facility. Emergency costs and emergency visits were excluded from the analyses because most beneficiaries included in our sample (96%) had none. This did not change our results.
Inpatient costs were standardized using the Diagnosis Related Groups (DRG) and the Centers for Medicare and Medicaid Services national average inpatient cost per DRG. Professional services costs were standardized using the procedure code and the Centers for Medicare and Medicaid Services Resource-Based Relative Value Scale unit for the procedure. All other costs were calculated using the total amount paid as submitted on the claim (total amount paid = amount paid by plan+amount paid out-of-pocket by patient including copay, deductible and coinsurance + amount paid for coordination of benefits). If an inpatient cost or professional services cost could not be standardized due to an invalid DRG or invalid procedure code, respectively, it was standardized using the total amount paid. The standardized costs were trimmed at the 99th percentile for each of the years after surgery.
Postsurgery outcomes were calculated beginning on the day of discharge and did not include the direct costs or health care utilization associated with the hospitalization for the bariatric surgery.
Analyses
To test for differences in the presurgery and postsurgery periods, we compared postsurgical costs and utilization with presurgical costs and utilization. All outcomes of postsurgery were measured in 1-year intervals. Cost and utilization variables were annualized for each individual based on at least 6 months of data.
To test for differences in the presurgery and postsurgery periods for the utilization outcomes, we used zero-inflated negative binomial regression to examine differences in inpatient days, primary care visits, and specialist visits. Owing to the repeated measurements among individuals, we used bootstrap methods in which resampling was done on the cluster level to estimate the variance of the parameters in the models. 13 To examine differences in costs, we used a 2-part model to account for the skewed nature of the data, where (1) logistic regression was used to estimate differences in the probability of any costs [reported as odds ratios (OR)] and (2) a generalized linear model with a log link function and a g distribution of the error term was used to estimate differences in costs between the presurgery and postsurgery intervals among those who had any costs (reported as cost ratios, CR). The first part of the model predicted the probability of an individual having any costs, and the second part predicted costs or utilization conditional on the individual having positive costs. Costs analyses were conducted using raw and truncated (at 99%) costs. We report the results from the analyses using raw costs because the difference between the 2 results was very small.
In all models, we adjusted for age, sex, health plan, and propensity to be obese-a measure validated in our claims data. 14 We also adjusted for diabetes severity at baseline, measured by the Diabetes Complications Severity Index, which had been previously validated as predictive of hospitalizations and death. 15 We validated the Diabetes Complications Severity Index in our own data, which lacked the 2 laboratory measurements that are in the initial scale. As in the original study, we found that this index is predictive of hospitalizations. To examine and control for comorbidities other than those that are diabetes related, we used the Johns Hopkins University Adjusted Clinical Groups Case-Mix System. 16 Adjusted Clinical Groups are mutually exclusive health status categories defined by the morbidity pattern, age, and sex. The comorbidity index is predictive of resources to be consumed in the next year. A higher comorbidity value indicates a higher morbidity burden.
Analyses were performed using (SAS, version 9.1; SAS Institute Inc., Cary, NC).
RESULTS
Our study sample included 31,940 individuals who received bariatric surgery; 21,898 individuals were excluded for not having diabetes, missing data on sex or for being outside of the age range; 2236 individuals were excluded for lacking at least 1 medical claim in the first 6 months of enrollment. Our final analytic sample included 7806 beneficiaries of which 6376 had 6+ months of enrollment in presurgery period. Table 1 presents the characteristics of the study sample in the presurgery period and during the 6 postsurgical years. Approximately 1 quarter of the sample was male with a mean age of 47 years in the presurgical period. The distribution of comorbidities and diabetes severity were similar during the presurgical and postsurgical periods. Table 2 presents the mean and median cost and utilization outcomes. The raw data demonstrate an increase in total health care costs in the postsurgical period, which was primarily due to higher inpatient and outpatient costs. We also observed an increase in inpatient days and a decrease in primary care and specialist visits in the postsurgery periods compared with the presurgery period. Appendix D, Supplemental Digital Content 4, http:// links.lww.com/MLR/A224 presents mean and median costs for laparoscopic bariatric surgery and open bariatric surgery separately. Total presurgical costs were lower among individuals receiving laparoscopic surgery. Similar to the overall sample, the increase in total health care costs postsurgery for both groups was primarily driven by higher inpatient and outpatient costs.
Change in Costs PostSurgery
Total Health Care Costs Figure 1 illustrates the adjusted odds of having any health care costs (left axis, black bars) and the adjusted ratio of total mean costs in the postsurgical period compared with the presurgical period (right axis, gray bars). In comparison with the presurgical period, the odds of having any health care costs were much lower in the postsurgery period and remained relatively flat over time. However, the absolute numbers of beneficiaries having no health care costs were low in the presurgical (0.05%) and postsurgical periods [post year 1: (0.3%), post year 2: (2.6%), post year 3: (4.8%), post year 4: (3.9%), post year 5: (4.1%), post year 6: (4.0%)]. The ratios of total health care costs among beneficiaries with any costs, however, were higher in the postsurgical period compared with the presurgical period, but declined overtime. In short, most beneficiaries had some health care costs after surgery, and among those who had costs, their health care expenditures were higher after surgery than before surgery. Point estimates are in Appendix C, Supplemental Digital Content 3, http://links.lww.com/MLR/A223.
Inpatient Costs
In contrast to the total cost results, the odds that beneficiaries would have any inpatient costs increased in the 3 years immediately after surgery, particularly the first postsurgery year, and then declined in the subsequent 3 years 
Outpatient Costs
The odds that beneficiaries would have any outpatient costs were lower in the postsurgery period compared with the presurgery period (post 1: OR = 0.50; 95% CI, 0.44-0.57; post 2: OR = 0.25; 95% CI, 0.22-0.29; post 3: OR = 0.17; 95% CI, 0.15-0.20; post 4: OR = 0.16; 95% CI, 0.14-0.19; post 5: OR = 0.15; 95% CI, 0.13-0.18; post 6: OR = 0.13; 95% CI, 0.10-0.16). However, among those beneficiaries 
Pharmacy Costs
The odds of having any pharmacy costs were lower in the postsurgery period compared with the presurgery period (post 1: OR = 0.98; 95% CI, 0.93-1.03; post 2: OR = 0.68; 95% CI, 0.63-0.74; post 3: OR = 0.57; 95% CI, 0.52-0.62; post 4: OR = 0.56; 95% CI, 0.50-0.62; post 5: OR = 0.51; 95% CI, 0.44-0.59; post 6: OR = 0.46; 95% CI, 0.37-0.58). However, among those beneficiaries who had any pharmacy costs, the ratios of costs were higher in the postsurgery period compared with the presurgery period (post 1: CR = 1.09; 95% CI, 1.04-1.14; post 2: CR = 1.04; 95% CI, 0.97-1.11); post 3: CR = 1.08; 95% CI, 1.00-1.16; post 4: CR = 1.10; 95% CI, 0.99-1.21; post 5: CR = 1.18; 95% CI, 1.03-1.35; post 6: CR = 1.20; 95% CI, 1.03-1.41).
Other Costs
Compared with the presurgery time, the odds of having any other costs (professional office and professional other such as visit costs, laboratory, and diagnostic imaging) were substantially lower in the postsurgery periods (post 1: OR = 0.12; 95% CI, 0.07-0.21; post 2: OR = 0.03; 95% CI, 0.02-0.06; post 3: OR = 0.02; 95% CI, 0.01-0.03; post 4: OR = 0.02; 95% CI, 0.01-0.03; post 5: OR = 0.01; 95% CI, 0.01-0.02; post 6: OR = 0.01; 95% CI, 0.01-0.02). However, the ratios of other costs, among those beneficiaries who had any other costs, were higher in the postsurgery periods (post 1: CR = 1.13; 95% CI, 1.07-1.19; post 2: CR = 1.13; 95% CI, 1.06-1.21; post 3: CR = 1.08; 95% CI, 1.01-1.16; post 4: CR = 1.07; 95% CI, 0.98-1.16; post 5: CR = 1.07; 95% CI, 0.98-1.17; post 6: CR = 1.01; 95% CI, 0.87-1.19).
Laparoscopic Bariatric Surgery Versus Open Bariatric Surgery
We additionally conducted post hoc, exploratory stratified analyses to examine costs for laparoscopic bariatric surgery and open bariatric surgery separately (see Appendix E, Supplemental Digital Content 5, http://links.lww.com/MLR/A225). We found that among beneficiaries in the laparoscopic and open surgical groups who had any costs; total costs, inpatient costs, and outpatient costs were higher after surgery than before surgery, as was seen in the combined results. However, among those who had any costs; pharmacy costs and other costs were high postsurgery in the laparoscopic group (as in the combined results), but were low postsurgery in the open surgical group (in contrast to the original results). As in the combined analyses, we observed similar patterns among both groups in the odds that beneficiaries would have any costs postsurgery and the ratio of costs among those beneficiaries who had any costs in the 6 years postsurgery. Figure 2 illustrates the adjusted odds of having no hospitalizations (left axis, black bars) and the adjusted ratio of hospitalizations in the postsurgery period compared with the presurgery period (right axis, gray bars). In comparison with the presurgical period, the odds of beneficiaries having no hospitalization were lower in the first 3 years postsurgery, almost the same in the fourth and fifth year postsurgery and higher in the sixth year postsurgery. Among those beneficiaries who had hospitalizations, the adjusted ratio of inpatient days was higher in the postsurgery period. Point estimates are in Appendix C, Supplemental Digital Content 3, http://links.lww.com/MLR/A223. Figure 3 illustrates the adjusted odds of having no specialist visits (left axis, black bars) and the adjusted ratio of specialist visits in the postsurgery period compared with the presurgery period (right axis, gray bars). The odds of beneficiaries having no specialist visits were higher in the postsurgery period compared with the presurgery period. Among those beneficiaries who had specialist visits, the adjusted ratio of specialist visits was lower in the postsurgery period. Point estimates are in Appendix C, Supplemental Digital Content 3, http://links.lww.com/MLR/A223. Figure 4 illustrates the adjusted odds of having no primary care visits (left axis, black bars) and the adjusted ratio of primary care visits in the postsurgery period compared with the presurgery period (right axis, gray bars). The odds of beneficiaries having no primary care visits were higher in the postsurgery period compared with the presurgery period. Among those beneficiaries who had primary care visits, the adjusted ratio of primary care visits was lower in the postsurgery period. Point estimates are in Appendix C, Supplemental Digital Content 3, http:// links.lww.com/MLR/A223.
Change in Utilization Postsurgery
Inpatient Days
Specialist Visits
Primary Care Visits
DISCUSSION
This study examined the impact of bariatric surgery on health care costs and utilization among adults with type 2 diabetes. For up to 6 years after having bariatric surgery, individuals with type 2 diabetes are more likely to have higher health care expenditures (eg, total mean costs were $9326 presurgery, $13,400 1 year after surgery, and $13,664 6 years after surgery), are more likely to have hospitalizations, but are less likely to have primary care and specialist visits compared with their respective costs and utilization before surgery. With the exception of our finding that specialist and primary care visits were lower after surgery, these results are contrary to what we hypothesized. Lower pharmacy costs in the postsurgery period among beneficiaries who received open bariatric surgery might reflect individuals in this group coming off their medications more quickly than individuals who received laparoscopic bariatric surgery. Although the change in pharmacy costs from presurgery to postsurgery was greater among the group receiving open bariatric surgery, absolute costs were lower in the laparoscopic group compared with the open group in both the presurgery and postsurgery periods.
This study contradicts previous research showing cost savings after bariatric surgery in a general population [17] [18] and among individuals with type 2 diabetes 10, 19 and research showing that bariatric surgery is cost-effective among the severely obese with diabetes. 20 It is consistent with recent research showing higher health care expenditures after bariatric surgery 21 and higher hospital use after Roux-en-Y gastric bypass. 22 Differences between our results and earlier studies could be due to the relatively large number of laparoscopic surgeries in our cohort (approximately 40%), our larger sample size or our considerably longer length of follow-up.
One possible explanation for our finding of higher costs and utilization after surgery could be complications after bariatric surgery, which have been documented in the literature, 23 particularly in the first postoperative year. 22 In our data, we found that individuals were much more likely to have costs in the first year after surgery than in the presurgical time.
Although these results do not support bariatric surgery as a cost savings procedure among individuals with diabetes, there is recent research, which suggests that bariatric surgery is safe in obese, diabetic patients 24 and has clinical benefits in this patient population. 25 Our finding that specialist and primary care visits declined after surgery deserves future study. On one hand, it is expected that individuals should have continued interactions with health care providers for preventative services and health maintenance for other comorbid conditions. On the other, benefits from surgery, such as weight loss, may have resolved diabetes in some patients and reduced their need for frequent clinical encounters.
In addition to the costs identified in this study, there is also lost productivity, including presenteeism and absenteeism, which may affect employers' decisions regarding the coverage of bariatric surgery. Recent research suggests that the annual cost attributable to obesity among full-time employees is $73.1 billion. 3 Individuals with a body mass index >35 kg/m 2 represent 37% of the obese population but are responsible for 61% of excess costs. Our finding that bariatric surgery is not cost saving among adults with diabetes may discourage employer interest in providing this coverage. However, a reduction or elimination of weightrelated comorbidities, improved quality of life, and improved mobility as a result of surgery may make this a valuable procedure in this population of patients.
This study was restricted to adults between the age of 18 and 64 years. The Medicare program, for adults aged 65 years and older, covers bariatric surgery for patients with coexisting conditions such as diabetes. 26 Given the rising prevalence of severe obesity in older adults 27 and the fact that the rate of increase of bariatric surgery is highest among the near elderly (age 55 to 64 y), 28 an increased number of Medicare beneficiaries are likely to become eligible for this procedure. Therefore, more research is needed to understand cost and utilization postsurgery among older patients with diabetes. Although we unfortunately lack race/ethnicity data on our study sample, previous research suggests that bariatric surgery is primarily utilized by privately insured, middleaged, white women, [29] [30] so our sample may not be a representative of all individuals with type 2 diabetes who are eligible for bariatric surgery. Additional research is also needed to understand differences in cost and utilization by demographic characteristics.
There are some limitations to this study, which suggest that it may be prudent to focus on the observed trends of utilization across time rather than the absolute numbers. Rules for billing patients immediately after surgery, particularly in the first 30 days, may differ by health plan. We, therefore, caution against the overinterpretation of costs in the first postsurgical year; for some patients in our cohort, there is utilization but no cost claims during that period. As there was no perfect overlap between costs and utilization (eg, not all outpatient costs were represented in outpatient utilization), we focused mostly on total costs. Small differences in how professional claims were standardized may reduce comparability of cost estimates across health plans. For all other claims (hospital, facility outpatient, pharmacy), costs were standardized in a consistent manner across plans. Only a portion of the sample (8%) had data out to 6 years. Therefore, the trends observed in this analysis may be biased by left censoring over time (not drop outs) because most patients in the reference group (presurgery) did not contribute to the later years of the analysis. We lack a control group of individuals who did not receive bariatric surgery. Without this comparison group, we cannot prove that the change in costs after surgery was due to the procedure. We assumed that severely obese individuals with diabetes would not have a spontaneous decrease in costs and utilization; it is more likely that their costs and utilization are stable or increase over time. Given the limitations of creating a control group from observational data-namely confounding by indication-we opted not to include one in this analysis.
We did not study individuals receiving usual diabetes care as the control group for 2 reasons. First, individuals with diabetes who receive bariatric surgery may have different preferences for medical care than individuals with diabetes who receive usual care. In particular, surgery recipients may be higher users of all health care services. Second, individuals with diabetes who receive bariatric surgery may have higher health care costs-due to a greater frequency of interactions with the health care system-to maintain the same clinical level as individuals with diabetes receiving usual care. In our dataset, individuals with diabetes who received usual care were clinically comparable with individuals with diabetes who received bariatric surgery (data not shown). Clinically, similar patients may have different utilization patterns due to patient preferences for care or provider preferences or different requirements of services to maintain this clinical similarity. Finally, we lack beneficiary information on race/ethnicity, so we are unable to examine patterns of cost and utilization among those subpopulations.
To conclude, this study uses a large dataset to examine the health care costs and utilization among adults with diabetes before and after bariatric surgery. We found that in the 6 years after surgery, bariatric surgery is not associated with lower costs among individuals with diabetes. We suggest, however, that even if bariatric surgery is not cost saving among adults with diabetes, a reduction or elimination of weight-related comorbidities, improved quality of life, and improved mobility may make this a valuable procedure in this population of patients. More research is needed to understand whether the higher costs and utilization we observed, persist among this population in the long term or reverse; to understand what clinical conditions and services drive this utilization; to understand whether an increase in elective procedures (eg, knee replacement, plastic surgery), not available to patients before surgery, partially explain increased cost and utilization postsurgery; and to understand clinical determinants of the postoperative costs of bariatric surgery among adults with diabetes.
